Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Company Overview

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape. Among these programs is an adenosine A2A receptor antagonist and a CD73-targeting monoclonal antibody, each advancing through Phase 1 and Phase 2 clinical trials. Additionally, the company is developing an ITK inhibitor aimed at enhancing T-cell activation. These assets are being evaluated both as monotherapies and in combination with checkpoint inhibitors across a range of solid tumor indications.

The company conducts its clinical trials in multiple regions, with ongoing studies in the United States and Europe. Corvus collaborates with leading academic centers and oncology consortia to accelerate trial enrollment and leverage translational research insights. This global trial footprint supports the company’s strategy of generating robust clinical data and exploring combination regimens that may address high-unmet-need cancers such as non–small cell lung cancer, renal cell carcinoma and colorectal cancer.

Founded in 2006 and headquartered in Carlsbad, California, Corvus Pharmaceuticals leverages a leadership team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Since its inception, the company has built a proprietary discovery platform and advanced multiple compounds from concept through early-stage clinical testing. As a Nasdaq-listed entity (NASDAQ: CRVS), Corvus continues to prioritize innovation in cancer immunotherapy with the goal of delivering meaningful new treatment options to patients worldwide.

Key Stats

• Today's Range: $11.04 to $11.99
• 50-Day Range: $11.50 to $17.85
• 52-Week Range: $3.55 to $26.95
• Volume: 1.18 million shs
• Average Volume: 2.63 million shs
• Market Capitalization: $935.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.33
• Consensus Rating: Moderate Buy

Corvus Pharmaceuticals Stock Analysis - MarketRank™

Corvus Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 673rd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Corvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Corvus Pharmaceuticals has a consensus price target of $33.33, representing about 198.3% upside from its current price of $11.18.

Amount of Analyst Coverage

Corvus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.70) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corvus Pharmaceuticals is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corvus Pharmaceuticals is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Corvus Pharmaceuticals has a P/B Ratio of 15.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

28.01% of the float of Corvus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 11.98, which indicates bearish sentiment.

Change versus previous month

Short interest in Corvus Pharmaceuticals has recently increased by 2.85%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corvus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Corvus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Corvus Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Corvus Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

8 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.70% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/05/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/08/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRVS
• CIK: 1626971
• Web: www.corvuspharma.com
• Phone: (650) 900-4520
• Fax: N/A
• Employees: 30
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Corvus Pharmaceuticals: $33.33
• High Price Target: $42.00
• Low Price Target: $27.00
• Potential Upside/Downside: +199.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.28 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.92%
• Return on Assets: -35.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.81
• Quick Ratio: 19.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.12 per share
• Price / Cash Flow: 91.51
• Book Value: $0.73 per share
• Price / Book: 15.23

Miscellaneous

• Outstanding Shares: 84,090,000
• Free Float: 67,524,000
• Market Cap: $935.08 million
• Optionable: Optionable
• Beta: 0.84